Dublin, May 06, 2025 (GLOBE NEWSWIRE) -- The "G-Protein Coupled Receptor (GPCR) Targeting: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global G ...

About Domain Therapeutics Domain Therapeutics is a clinical-stage biopharmaceutical company developing highly differentiated therapeutic strategies targeting G protein-coupled receptors (GPCRs), a ...

本文聚焦传统药物与 GPCR，介绍相关研究进展及平台策略，助力新药研发。 传统药物与 GPCR 研究背景 传统药物源自草药、药用动物和真菌，在全球使用历史悠久。2023 年 5 月第 76 届世界卫生大会 ...

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR ...

In trading on Wednesday, shares of Structure Therapeutics Inc (Symbol: GPCR) entered into oversold territory, hitting an RSI reading of 28.5, after changing hands as low as $27.49 per share.

PTH1R is a G protein coupled-receptor (GPCR), part of a family of receptors that regulate a wide range of physiological processes. The role of these receptors in both health and disease is known ...

In this article, we are going to take a look at where Structure Therapeutics (NASDAQ:GPCR) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk ...

Most protein-targeting drugs are prizes that drug developers have unearthed from G protein–coupled receptor (GPCR) interactomes. So, when GPCR-targeting drugs become harder to find, one might ...